| Model Number |
298519 |
| Medical Device Problem Code |
Incorrect, Inadequate or Imprecise Result or Readings (1535)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
10/05/2021
|
|
Type of Reportable Event
|
Malfunction
|
|
Event or Problem Description
|
|
It was reported that during use with bd bbl¿ macconkey ii agar with sorbitol 6 plates had subsurface growth.There was no report of patient impact.The following information was provided by the initial reporter: macconkey ii w/ sorbitol plates failed sterility qc.6 of 10 sterility plates had subsurface growth.
|
| |
|
Additional Manufacturer Narrative
|
|
A device evaluation is anticipated, but has not yet begun.Upon completion of the investigation, a supplemental report will be filed.
|
| |
|
Event or Problem Description
|
|
It was reported that during use with bd bbl¿ macconkey ii agar with sorbitol 6 plates had subsurface growth.There was no report of patient impact.The following information was provided by the initial reporter: macconkey ii w/ sorbitol plates failed sterility qc.6 of 10 sterility plates had subsurface growth.
|
| |
|
Additional Manufacturer Narrative
|
|
H.6 investigation summary: during manufacturing of material 298519, media is formulated and sent through a high temperature short time sterilizer to remove bioburden.The petri dishes are subjected to uv radiation to decrease bioburden.The petri dishes are filled in a positive pressure hepa filtered environment.The filled plates are cooled and immediately wrapped into sleeves to decrease the introduction of microbes.Sleeves are then packaged into cartons and then transferred to a refrigerated truck (2 to 8 degrees c) for shipment to the distributor.Bd distributors are provided with the storage guidelines for the shipping and handling of bd media of 2 to 8 degrees c in a dark place.The batch history record for batch 1216762 was satisfactory and no quality notifications were generated during manufacturing and inspection.The release testing that is performed on this product does include bioburden testing.A sample of plates are incubated at 25 degrees c and at 35 degrees c for approximately 72 hours.All bioburden testing performed on this batch was satisfactory per bd internal procedures.Affected product does not have any sterility claims; the product is tested for bioburden prior to release to ensure that it conforms to product specifications.However, this does not ensure that the end-user will not receive a contaminated plate.The complaint history was reviewed, and no other complaints have been taken on batch 1216762.Retention samples from batch 1216762 were not available for inspection.Eighty plates from batch 1216762 were returned as eight unopened sleeves shipped in a box.Prior to inspection, plates were incubated at 20 to 25 degrees c (4 sleeves) and 33 to 37 degrees c (4 sleeves).Plates were inspected at 3 days incubation and 0/80 plates had microbial growth (time stamps 0250-0252).No photos were received for investigation.A trend was identified for contamination and investigation found opportunities for bioburden reduction in the manufacturing process.A capa (corrective and preventative actions) has been initiated and involves implementing additional cleaning events and evaluation of manufacturing procedures focused on in-process bioburden reduction.Additional trainings are planned with an ongoing training review for cleaning processes.This complaint can be confirmed by the identified trend.Bd will continue to trend complaints for contamination.H3 other text : see h.10.
|
| |
|
Search Alerts/Recalls
|